Small-molecule drug discovery
Raised to date
$9.1M
of $10M offered across 2 Form D filings
Carna Biosciences, Inc. is a biotechnology company dedicated to drug discovery and the development of small molecule drugs. The company aims to address unmet medical needs by offering innovative therapeutic solutions in areas where current treatments are either inadequate or non-existent.
Carna Biosciences stands out through its focused approach on developing small molecule drugs, targeting diseases with insufficient treatment options to make significant contributions to improving health outcomes.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jun 11, 2026 | Equity | $9.1M/ $10M | Form D/A |
| Feb 5, 2025 | Equity | $3.4M/ $10M | Form D |
Pharmaceutical Development
Carna Biosciences spearheads a robust drug discovery business, primarily focusing on the development of small molecule drugs. Their research is driven by a commitment to innovation, with an emphasis on creating novel therapeutic solutions for challenging medical conditions.
Built for
Healthcare and pharmaceutical industry
